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Results: We have enrolled 13 men and 16 women, median age 65 years 
old. In 29 evaluable patients, only 1 episode of febrile neutropenia has 
been documented and was related to aspergillus pneumonia. Twenty of 
29 patients have developed grade 3/4 neutropenia (only 4 grade 4), all 
requiring dose reductions. Ten of 29 patients have developed grade 3/4 
thrombocytopenia, and an additional 11 of 29 had grade 1 or 2 throm-
bocytopenia. No signiﬁcant bleeding episodes have been documented, 
though grade 1/2 hemorrhoidal bleeding was documented in 4/29 and 
grade 1 hematuria occurred in 4/29 patients. Anemia has been mild 
with grade 3 anemia in only 5 of 29 patients. Non-hematologic toxicity 
was generally minor, with fatigue being the principal toxicity; adverse 
events possible related to BV include grade 3 hypertension and angina 
(1 pt), grade 1 hypertension (1 pt), perforated ulcer (1 pt) and epistaxis 
(grade 3 in 1 pt, grade 1 in 11 pts). No thrombosis has been reported 
and grade 1 proteinuria in only 1 patient. There have been no fatal 
toxicities. 
Conclusions: To date, the addition of BV to GC in pts with NSCLC is 
generally well tolerated, and toxicities have been expected and manage-
able. Enrollment is ongoing. 
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Background: It is apparent that there is a cluster of clinical factors that 
predict for an increased rate of response and survival to the epidermal 
growth factor (EGFR) tyrosine kinase inhibitors. However, the current 
knowledge of EGFR DNA mutations and gene expression is insuf-
ﬁcient to explain these observations. The purpose of this study is to 
enrich the population of patients more likely to respond to the EGFR 
inhibitor, erlotinib, and to perform extensive genomic screening to 
identify tumour-speciﬁc genome abnormalities to predict patterns of 
response and resistance. 
Methods: Eligibility criteria: stage IIIB/IV NSCLC; chemo-naive; ≥ 
1 measurable lesion; ECOG ≤2; adequate organ function; and at least 
2 of the following 4 criteria: women, never-smokers, Southeast Asian 
extraction, adenocarcinoma (ACA) and/or bronchioloalveolar carci-
noma. All patients must consent to a baseline fresh tumour biopsy and 
serum sample; biopsies during treatment and at disease progression are 
optional. Tumour cells are isolated by laser microdissection following a 
pathology review. Tumour genomic DNA is applied to high-resolution 
genomic microarrays to detect tumour-speciﬁc changes in copy number 
and/or genotype at multiple sites across the genome, including EGFR 
and exons encoding genes with altered copy number. Erlotinib 150mg 
p.o. daily is given on a continuous basis until disease progression.
Results: From Sept-06 to Feb-07, 20 patients (pts) have been enrolled. 
Median age 62 (range 43- 78); 17 females and 3 males; 18 never 
smokers, 2 former and 0 current smokers. PS 0-4; 1 - 13; 2 - 3. Ethnic-
ity: 5 Caucasian and 15 Asian (including China-7 & Hong Kong-3). 
Pathology: 17 ACA; 1 squamous carcinoma; 2 NSCLC NOS. As of 
Feb-07, 16 pts have received >8 weeks of treatment or have been taken 
off study for progressive disease. Toxicities consist of expected rates of 
rash and diarrhea. Responses: PR - 5; SD - 6; PD - 5; 4 pts are too early 
to assess (4 weeks only). Thus 11 of 16 (69%) have not progressed at 8 
weeks. All pts had fresh tumour samples collected. Laser microdissec-
tion and tumour DNA extraction was performed and genomic analysis 
is underway.
Summary: In this clinically selected population treated with ﬁrst-line 
erlotinib, the rate of non-progression at 8 weeks is acceptable. A unique 
correlation of extensive molecular data obtained from fresh tumour 
samples, data on pre-drug genetic abnormalities and post-drug clinical 
response, time to progression, and survival will be performed in all 
patients enrolled in this study. This work represents an effort to go 
beyond EGFR analysis and uncover novel features of the lung cancer 
genome that may help predict drug response and further understanding 
of tumour biology.
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Background: Geﬁtinib is a selective inhibitor of the epidermal growth 
factor (EGFR) tyrosine kinase and approved for use as salvage therapy 
in advanced non-small cell lung cancer (NSCLC). We retrospectively 
analyzed 359 Korean NSCLC patients treated with geﬁtinib to identify 
clinicopathologic parameters predictive of response and survival 
beneﬁt. 
Methods: Data from NSCLC patients treated with geﬁtinib at Samsung 
Medical Center in Korea from Jan 2003 until Dec 2005 were collected. 
Patients were treated with geﬁtinib 250mg per day until progression 
or development of toxicity. Response evaluation with spiral CT scan 
was performed at 4-8 weeks after geﬁtinib treatment. Multivariate Cox 
regression hazards analysis was performed to determine the combined 
effects of clinicopathological variables in relation to tumor response 
and overall survival.
Results: For 331 evaluable patients the overall response rate was 
25.1% (83/331; 3 CR, 80 PR) and disease control rate was 48.6%. 
Median age was 60 years (range 25-86). 236 patients (65.7%) were 
male and 154 patients (42.9%) were never-smokers. The most com-
mon histological subtype was adenocarcinoma (67.1%) and 183 
patients(51.0%) had a PS≥2. In a large majority of case (90.0%), 
cytotoxic chemotherapy had been administered before treatment of 
geﬁtinib and most of them received platinum-based combination 
regimens(84.4%) as the ﬁrst-line treatment. At a median follow-up of 
30 months, the median survival for all the 359 patients from the date 
of geﬁtinib administration was 6.2 months with 1 year-survival rate of 
32.2%. The median survival time calculated from the ﬁrst diagnosis of 
advanced/metastatic or recurrent disease was 19.7 months. Good per-
formance status (PS 0-1), never-smoker and development of skin rash 
after administration of geﬁtinib were statistically signiﬁcant favorable 
predictive markers for tumor response by multivariate analysis. Sig-
niﬁcant predictors for favorable survival were good performance status 
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(PS 0-1), never smoker, and development of skin rash with geﬁtinib ( 
p<0.001, p=0.031, p<0.001, respectively). 
Conclusion: This analysis suggests that patients with good perfor-
mance status and never smoker and development of skin rash may 
beneﬁt from geﬁtinib treatment in terms of tumor response as well as 
survival. 
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Background: Geﬁtinib (Iressa) is active as a single agent in the 
treatment of select patients with recurrent non-small cell lung cancer 
(NSCLC). The clinical characteristics of patients treated with geﬁ-
tinib at our department identiﬁed predictive variables associated with 
survival .
Methods: Patients (n = 60) with advanced NSCLC were treated with 
geﬁtinib (250 mg) upon progression with chemotherapy. N-score=o is 
deﬁned as N0,N1 or no-bulky and single N2,N-score=1 is deﬁned as 
bulky or multiple N2 or N3 or distant lymph node.
Results: Partial responses were noted in 18 patients (30%) and disease 
stabilization in 25 (41.7%) patients. The median survival (MS) was 
51weeks and median time to progression was 24 weeks. The predic-
tive factors analyzed were gender,age, tumor histology, T,N, N-score, 
performance status (PS) and weight lost. Tumor histology (p=0.008) 
and N-score (P <0.001)(not N) were predict factors in Cox regression 
model .
Conclusions: Tumor histology and N-score could predict survival time 
for recurrent NSCLC patients treated with geﬁtinib 
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A new class of drugs that have the ability to inhibit the epidermal 
growth factor receptor (EGFR), namely geﬁtinib, erlotinib and cetux-
imab, is being used for treatment of patients with colorectal, head and 
neck, or non-small cell lung cancer (NSCLC) refractory or intolerant to 
chemotherapy.
Erlotinib (EGFR-speciﬁc tyrosine kinase inhibitor) is currently been 
used for the treatment of patients with locally advanced or metastatic 
NSCLC after failure of at least one previous chemotherapy regimen, it 
is taken orally and its most frequent undesirable side-effects are gastro-
intestinal disturbance and, cutaneous alterations (acneiform rash, skin 
dryness, paronychia, nasal or oral ulcers, urticariform rash and sebor-
rhoeic dermatitis), that are observed in 56% and 75%, respectively. 
This skin toxicity is a pharmacologic class effect rather than a hyper-
sensitivity reaction to the drug. It appears to imply a better response 
from the tumor to erlotinib and is dose dependent but not correlated 
with duration of therapy. 
Dermatologists have now the responsibility to assist usage of this new 
therapy without lowering of dosis so an effective oncologic manage-
ment is achieved.
We present 5 cases of patients that underwent erlotinib treatment for 
NSCLC that presented cutaneous alterations, namely an acneiform 
reaction, hirsutism and paronychia and how we manage them. We’ll 
emphasize on cumulative dosis of the drug, delay to the appearance 
of the cutaneous side effects and time needed for their remission after 
treatment. 
This work intends to point out the need for dermatologists to be aware 
of the new oncologic drugs that are being developed, the alterations 
they cause in the skin and the need for a consensus in how to treat them 
so we can help the patient comply with the oncologic treatment and 
hopefully improve its quality of life and survival. 
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Introduction: IMO-2055 is a novel synthetic oligonucleotide ago-
nist of TLR9 that stimulates innate and adaptive immune responses 
in preclinical studies. IMO-2055 was well tolerated in a phase 1 
monotherapy study in refractory solid tumor patients at dosages up to 
0.64 mg/kg/week SC, with optimal immune system activation, based 
on the parameters evaluated, demonstrated between 0.16 and 0.32 
mg/kg/week. Mild, transitory lymphocytopenia on day 2 (d2) was an 
expected pharmacology. Adverse events (AEs) were mild-moderate 
injection site reactions and ﬂu-like symptoms. In preclinical studies, 
IMO-2055 was shown to potentiate the activity of standard oncology 
therapies, including chemotherapy, monoclonal antibodies and targeted 
agents. Combining IMO-2055 with gemcitabine in a mouse NSCLC 
model (A549) led to greater suppression of tumor growth than either 
agent alone. The carboplatin-gemcitabine combination had acceptable 
activity and a different safety proﬁle vs. standard cisplatin-gemcitabine 
in NSCLC (Zatloukal et al, Lung Can 2003). Based on these data, we 
investigated the combination of IMO-2055, gemcitabine and carbopla-
tin in advanced solid tumor patients. 
Methods: We combined IMO-2055 at 4, 8 or 12mg total dose per SC 
injection with gemcitabine 1000mg d1 and 8 IV plus carboplatin AUC5 
d1 IV q3w. The initial IMO-2055 schedule was d1, 8, 15; schedules of 
d2, 9 and d9, 16 were added to optimize IMO-2055 administration rela-
tive to the nadirs of chemotherapy-induced hematological toxicity. Pts 
had refractory solid tumors with ≤ 2 prior regimens and fulﬁlled stan-
dard phase 1 entry criteria. The primary endpoint was to identify MTD; 
secondary endpoints included safety and response rate (RECIST). 
Results: 18 pts were treated from November 2005 to February 2007 for 
a median of 3 cycles (1-15) in 17 evaluable pts (7 male; 10 female): 7 
NSCLC, 3 neuroendocrine, 2 unknown primary, 1 each of melanoma, 
esophagus, head and neck, breast and cholangio- carcinomas. Median 
ECOG PS was 1 (0-1) with median 1 prior chemotherapy and 53% 
prior radiotherapy. Grade 4 neutropenia or thrombocytopenia have 
been identiﬁed as DLTs in 2/5 pts at IMO-2055 12mg d1, 8, 15; 2/3 pts 
at 8mg d2, 9; 1/2 pts at 12mg d9, 16; and 0/3 pts at 8mg d9, 16. Most 
